Rigel Pharmaceuticals reported $48.53M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Amgen USD 13.19B 799M Sep/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Celldex Therapeutics USD 26.95M 20.5M Sep/2026
Daiichi Sankyo JPY 637.85B 188.04B Jun/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Halozyme Therapeutics USD 1.03B 866.85M Sep/2026
Heron Therapeutics USD 11.6M 9.13M Sep/2026
Intrexon USD 9.34M 1.77M Jun/2024
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 55.96M 950.74M Sep/2026
MacroGenics USD 49.03M 64.88M Sep/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Regeneron Pharmaceuticals USD 3.66B 1.2B Sep/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Veracyte USD 199.83M 99.69M Sep/2026